MALE HORMONES
Home | DHEA cheap legal popular steroid | Viagra & Erectal Dysfunction | TESTOSTERONE-CONCISE NOTES | TESTOSTERONE--EXTENSIVE NOTES | Pharmacology textbook, chapter on TESTOSTERONE | Methods of Testosterone Supplementation | Testosterone for Women? | TTT GOOD FOR THE BRAIN--2 studies | MALE-MENOPAUSE-2ND ARTICLE | MALE MENOPAUSE | DOUBTS ON TTT & ANDROSTENE | OVER-THE-COUNTER-SOLUTION | HOT NUTS: THE CONSEQUENCES | Oral hGH, what works? | HGH-HYPE & FACTS | HGH-POSITIVE FINDINGS--HARVARD | TESTOSTERONE NOT LINKED TO PROSTATE CANCER--latest study shows | Cialis better than Viagra | VIAGRA SAFE | circumcision reduces HIV risk 60% | Prostate Disease | Prostate biopsy, PSA test, prostatectomy--Urology textbook | Prostate cancer and blocking testosterone | LINKS

TESTOSTERONE NOT LINKED TO PROSTATE CANCER--latest study shows

         Contrary to accepted wisdom.  It has been long assumed that like estrogen, which stimulates the progress of breast cancer, testosterone stimulates the growth of testicular and prostate cancer.  Thus it is common prescribed for these male cancers a drug that blocks testosterone.  I will assume that these observations are well supported; however, the question remains, what is the effect of elevating the level of testosterone upon those who don’t have such cancers.  Will it stimulate the progression of pre-cancerous microscopic tumors into cancer?  This study addresses that question and answers it in the negative.  Testosterone does not accelerate the transformation of these pre-cancerous tumors into cancer.  The same has been repeatedly concluded, for other 30 years about estrogen—though there are some who will point to a few studies that support the opposite conclusion.  Their error comes from the fact that estrogen accelerates the growth of cancer, not the conversion into cancer.  Thus for only the first couple of years of taking estrogen replacement, there will be a moderate increase in clinical breast cancers.
        This study is of the serum levels of testosterone related androgens and their metabolites.  The serum levels of those with prostate cancer and those without were essentially the same.--jk 

Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies

 

Eaton NE, Reeves GK, Appleby PN, Key TJ.

 

Imperial Cancer Research Fund, Cancer Epidemiology Unit, Radcliffe Infirmary, Oxford, UK.

 

This paper presents a quantitative review of the data from eight prospective epidemiologieal studies, comparing mean serum concentrations of sex hormones in men who subsequently developed prostate cancer with those in men who remained cancer free. The hormones reviewed have been postulated to be involved in the aetiology of prostate cancer: androgens and their metabolites testosterone (T), non- SHBG-bound testosterone (non-SHBG-bound T), di-hydrotestosterone (DHT), androstanediol glucuronide (A-diol-g), androstenedione (A-dione), dehydroepiandrosterone sulphate (DHEAS), sex hormone binding globulin (SHBG), the oestrogens, oestrone and oestradiol, luteinizing hormone (LH) and prolactin. The ratio of the mean hormone concentration in prostate cancer cases to that of controls (and its 95% confidence interval (CI)) was calculated for each study, and the results summarized by calculating the weighted average of the log ratios. No differences in the average concentrations of the hormones were found between prostate cancer cases and controls, with the possible exception of A-diol-g which exhibited a 5% higher mean serum concentration among cases relative to controls (ratio 1.05, 95% CI 1.00-1.11), based on 644 cases and 1048 controls. These data suggest that there are no large differences in circulating hormones between men who subsequently go on to develop prostate cancer and those who remain free of the disease. Further research is needed to substantiate the small difference found in A-diol-g concentrations between prostate cancer cases and controls.

 

Publication Types:

•  Meta-Analysis

 

CURRENT MEDICAL PRACTICE FOR THE PRESCRIBING OF TESTOSTERONE REQUIRES AN EXAMINATION FOR PROSTATE CANCER.  CURRENTLY CARE PROVIDERS DO NOT CONSIDER TESTOSTERONE A SIGNFICANT CAUSE FOR PROSTATE CANCER, BUT RATHER THAT IT IS INVOLVED IN ITS AETIOLOGY.